Presentation is loading. Please wait.

Presentation is loading. Please wait.

Aspects on the Role of the Pathologist in CRC Aspects on the Role of the Pathologist in CRC Najib Haboubi FRCS FRCP FRCPath D Path Professor of Health.

Similar presentations

Presentation on theme: "Aspects on the Role of the Pathologist in CRC Aspects on the Role of the Pathologist in CRC Najib Haboubi FRCS FRCP FRCPath D Path Professor of Health."— Presentation transcript:

1 Aspects on the Role of the Pathologist in CRC Aspects on the Role of the Pathologist in CRC Najib Haboubi FRCS FRCP FRCPath D Path Professor of Health Sciences, Liver and Gastrointestinal Pathology. University Hospital of South Manchester UK

2 Selected Topics Multi Disciplinary Meeting(MDT). Resection Margins (Long and Circumferential). Assessment after CRT for Rectal Cancer

3 Background In UK (60m) there are 35,000 new cases and 16,000 deaths per annum. New patterns in some parts of the world. In India 6 th commonest among female and 9 th amongst male.

4 Accurate Pathological Reporting Confirm diagnosis. Inform prognosis. Plan treatment of individual patients. Audit pathology services. Evaluate and audit the quality of other services like radiology, surgery and oncology. Collect accurate data for cancer registration and epidemiology. Facilitate high quality research. Plan service delivery.

5 Multi Disciplinary Team (MDT) Colorectal Surgeons Radiologists. Pathologists. Oncologists. Specialist Nurse. Hepatobiliary(Thoracic) Surgeon Stoma Nurse. Clinical geneticist / counsellor. Social worker. Clinical trials coordinator or research nurse. GP Dietician. Gastroenterlogist


7 Video Conferencing

8 MDT Takes place at regular intervals Encourages a more efficient and team working atmosphere. Have a consensus approach to treatment according to agreed protocols. Quick and appropriate referral pattern. Audit surgical treatment. Audit pathology reports.



11 Evidence Based

12 Second Edition 2007 Few important additions.



15 Assessment of RM Assessment of RM Longitudinal Circumferential / lateral /Radial / non peritonealised resection margin.

16 Minimum safe Longitudinal Margin < 1cm

17 Reappraisal of 5 cm rule of distal excision for carcinoma of rectum Williams, Dixon and Johnston. Br.J.Surgery 1983

18 Conclusion The application of the 5 cm rule of distal excision may cause patients with low rectal cancer to lose their anal sphincter unnecessarily.

19 Kirwan, Drumm, Hogan, Keohane Determining safe margin of resection in low anterior resection for rectal cancer. Br.J.Surg cm

20 Declining indication for APR resection in favour of AR Kirwan, ORiordain and Waldron….. Br.J.Surg 1989

21 Karanjia, Schache, North and Heald Close shave in anterior resection. Br.J.Surg cm

22 Conclusion Reduction of resection margins (provided TME and washout is properly performed) does not increase local recurrence or compromise survival.

23 DCR 2011

24 Conclusion Does not influence Oncological outcome

25 Additions in the 2 nd edition (1) Documentation type of procedure. For rectal cancer, it is expected to have more AP than APR.

26 National Audit AR 1670 APR 746 Hartmans 299 There is a trend of increase the AR over APR due to: Better preoperative treatment Better imaging modalities and Better surgery. Good surgeons should be able to undertake AR for tumours above 5cm from anal verge.

27 Currently Increasingly there are surgeons who practice restorative surgery for ultra low rectal cancer: 3 cm

28 Circumferential (CRM) / Lateral / Radial / Non Peritonealised Resection Margin (NPRM)


30 Circumferential resection margin Involvement (CRMI) 1mm or less High Local Recurrence. Low Survival. Poor Standard of Surgery. Aggressive Disease. Tumour Location. Male gender.





35 Addition to the 2 nd edition (2) Addition to the 2 nd edition (2) Grading of surgical plane of resection in rectal cancer. The continuous feedback to surgeons may lead to improve quality of surgery.

36 Macroscopic Evaluation of Rectal cancer Resection Specimens Clinical Significance of the Pathologist in Quality Control. 2 years follow up. Iris Nagtegaal et al J Clin Oncol 2002, 20:

37 Macroscopic Grading of TME A (3) ( Good). Complete. Smooth, no coning, defect >5 mm and regular CRM C (1) ( Poor). Defects down to the Muscularis,conning, no bulk and irregular CRM B(2).Nearly complete. Defect present but Muscularis is not apparent(except at the insertion of LA) and irregular CRM.


39 Results GradeA&B - good and acceptable C- Poor Local Recurrence 8.7%15% Local recurrence and Distant Metastasis 20.3%36.1% 2 Year Survival90.5%76.9%

40 Addition to the 2 nd edition (3) Measurement of tumour beyond the muscularis propria recorded in mm. This is to: a/ facilitate audit of preoperative imaging of extramural spread as it is of importance in selecting patients of rectal cancer to choose a therapy arm. b/ It has a prognostic implication for rectal cancer. 5mm or more is associated with adverse prognosis.


42 Addition to the 2 nd edition (4) Addition to the 2 nd edition (4) Recording tumour involvement of the NPRM in colonic tumours (in addition to rectum) like the caecum. These patients may be selected for post operative adjuvant therapy. Bateman et al J Clin Path 2005 and Quirke et al 2006 J Path

43 Addition to the 2 nd edition (5) Addition to the 2 nd edition (5) Recording serosal ( peritoneal surface) involvement. Tumour cells visible either on the peritoneal surface or free in the peritoneal cavity carry bad prognosis

44 Influence of local peritoneal involvement on pelvic recurrence and prognosis in rectal cancer. Shepherd, Baxter and Love J. Clin. Path 1995

45 Local Peritoneal Involvement 1. Detected in 25.8% (54/209) of cases. 2. Showed considerable prognostic disadvantage in curative and non curative cases. 3. May be an important factor in local recurrence of upper rectal cancers.

46 The Prognostic Importance of Peritoneal Involvement in Colonic Cancer: a Prospective Evaluation Shepherd et al Gastroenterology 1997 Strong predictive value for local recurrence / persistent disease specially when there is mucinous differentiation.

47 Additions in the 2 nd edition (6) Recording of marked or complete tumour regression in patients with rectal cancer that have received adjuvant chemo / radiotherapy (CRT)

48 Rectal cancer that have received adjuvant R/CRT. Tumour regression is associated with improved prognosis.

49 Pathologist should record marked or CTR Rectal cancer that have received adjuvant R/CRT. Tumour regression is associated with improved prognosis.

50 1895 XRT 1 st used

51 BMJ 1897

52 Rationale for combined CRT for Rectal Cancer Chemotherapy increases tissue sensitivity towards radiation. Radiation stops proliferation. Both tumourus and non tumourus tissue are affected.

53 Changes afflicting Tumour

54 Short course preoperative radiotherapy interferes with the determination of pathological parameters in rectal cancer Iris Nagtegaal et al. J Path 2002,197: patients(706 TME alone, 598 TME+RT) No change in stage (No change in depth and although there is decrease in no. of LN retrieval but not in +ve lymph nodes)!! Three folds decrease in local recurrence.

55 Long course CRT Improves staging (depth and LN status). Associated with c&pCTR

56 Classifications of Regression Mandard : Cancer 1994,73;2680. (1-5) Dworak : Int CRD 1997,12;19. (0-4) Wheeler : DCR 2002,45;1051. (1-3) Ryan : Histopathol 2005,47;141.(1-3) PRINCIPLE Tumour Volume V Fibrosis.

57 Discrepancy in Staging AuthorGrade Best Response (pCR) Worst Response Mandard1-515 Dworak0-440 Wheeler1-313 Ryan1-313

58 Ryans modification of Mandards 5 point system G1: No viable cancer cells (pCTR) : Single cells or small groups of cancer cells. G2: Residual cancer cells outgrown by fibrosis. G3: Significant fibrosis outgrown by cancer cells. : No fibrosis with extensive residual cancer.

59 Pathological response following long- course neoadjuvant CRT for locally advanced rectal cancer Rayan et al Histopathology:2005,47: patients G1, G2,G3. none of the G1&2 (excellent and good) had local recurrence after mean 22 months.







66 CTR we must be clear either pathologic (pCR) or clinical (cCR) 15-30% achieve pCR 25-50% of cCR are confirmed as pCR at subsequent surgery.

67 What do we do when there is cCR?

68 Operative Versus Non Operative Treatment for Stage 0 Distal Rectal Cancer Following Chaemoradiation Therapy Long- term Results Angelita Habr-Gama, et al Ann Surgery 2004

69 Results 26.8% of patients who received CRT developed complete clinical tumour response (observational group). Full thickness biopsy? The five-year overall and disease-free survival rates were 88% and 83% in Resection Group and 100% and 92% in Observation Group

70 Conclusion Stage 0 rectal cancer disease is associated with excellent long-term results irrespective of treatment strategy. Surgical resection may not lead to improved outcome in this situation and may be associated with high rates of temporary or definitive stoma construction and unnecessary morbidity and mortality rates.

71 Complete Clinical response After Preoperative CRT in Rectal cancer Is Wait and See Policy Justified? Glynne-Jones et al DCR 2008 Narrative Review of 246 studies

72 Results The end point of complete clinical response is inconsistently defined. Insufficiently robust. Partial concordance with pathological complete response.

73 Conclusion The rationale of wait and see policy when complete clinical response status is achieved relies on retrospective observations which are insufficient to support such policy. EXCEPT In patients who are recognised as unfit or refused surgery

74 What do we do when there is cCR? There are at least one trial in UK and an audit in the North West Region. Registering ALL cases with cCR and cPR. Outcome?

75 `

76 The effective management of CRC requires The involvement of the histopathologist at various stages of treatment pathway. Diagnostic. Therapeutic. Audit. Research.




80 FACTORS INFLUENCING BIOLOGICAL RESPONSE Related to host and tissue. Related to therapy

81 Factors related to therapy Dose. High dose more toxic Field. Large field more toxic. Concomitant chemotherapy is more toxic Post operative RT is more toxic than pre operative RT


83 Acute radiation colitis in patients treated with short term preoperative radiotherapy for rectal cancer Leupin et al (Switzerland) Am J Surg. Path. 2002

84 Radiation colitis Short Course Sever mucosal inflammation. Prominent eosinophils. Crypt disarray Crypt epithelial damage. Nuclear abnormality Apoptosis of crypt epithelium. Either clinically silent or quick recovery. Long Course These features are either absent or rarely detected.

85 The Light and Electron Microscopic Features of Early and Late Radiation- Induced Proctitis Haboubi, Rowland, and Schofield Am.J.of Gastro. 1988






91 Conflicts in the literature

92 How SC differs from LC in pathological and clinical parameters 78 patients(SC 65, LC13) Age (average 67 years) 54 males and 25 females Mean follow up 56 months(4-105) AR in 31 cases; APR in 47cases.

93 Results 1 32 Responders (Ryan grade 1 and 2) 10(76%) of LC vs. 22(33%)SC.

94 Results 2 7 patients had local recurrence (6SC,1LC) Regression did not correlate with local recurrence

95 Result 3 Regression did not correlate with overall survival

96 Prognostic Significance of Tumour Regression After Preoperative CRT for RC Rodel et al.J Clin Oncol 2005,23:8688 G 4 (Good) in 10.4% DFS 86%. G 2&3 DFS 75% G 0&1(Bad) >10% DFS 63%

97 Result 4 Overall mortality correlated with lymph node positivity (p=0.009) 29% of responders were LN+ve versus 48% non responders

98 Absence of LN in the resected specimen after Radical Surgery for Distal Rectal Cancer and Neoadjuvant CRT: What does it mean? Habr-Gama et al DCR 2008,51; (11%) patients had no LN.5YDFS 74% 171(61%) had ypNO. 5YDFS 59% 78(28%) had yp(N+). 5YDFS 30%

Download ppt "Aspects on the Role of the Pathologist in CRC Aspects on the Role of the Pathologist in CRC Najib Haboubi FRCS FRCP FRCPath D Path Professor of Health."

Similar presentations

Ads by Google